{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:07:09Z","timestamp":1787677629007,"version":"build-2784847793"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.diabres.2022.110161","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T02:52:39Z","timestamp":1668653559000},"page":"110161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"194","author":[{"given":"Shunichiro","family":"Tsukamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryutaro","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Urate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Azushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushi","family":"Uneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryu","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Kanaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Wakui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouichi","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.diabres.2022.110161_b0005","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2021.05.023","article-title":"Management of diabetes mellitus in patients With CKD: Core Curriculum 2022","volume":"79","author":"Hahr","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"10.1016\/j.diabres.2022.110161_b0010","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrcardio.2016.48","article-title":"Global cardiovascular protection in chronic kidney disease","volume":"13","author":"Ruiz-Hurtado","year":"2016","journal-title":"Nat Rev Cardiol"},{"issue":"8","key":"10.1016\/j.diabres.2022.110161_b0015","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/00325481.2017.1358064","article-title":"Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus","volume":"129","author":"Yandrapalli","year":"2017","journal-title":"Postgrad Med"},{"key":"10.1016\/j.diabres.2022.110161_b0020","first-page":"gfac140","article-title":"High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database [published online ahead of print, 2022 Apr 7]","author":"Fried","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1016\/j.diabres.2022.110161_b0025","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1007\/s12325-022-02223-0","article-title":"A narrative review of diabetic kidney disease: previous and current evidence-based therapeutic approaches","volume":"39","author":"Mima","year":"2022","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.diabres.2022.110161_b0030","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11892-022-01461-4","article-title":"Mineralocorticoid receptor antagonists in the treatment of diabetic kidney disease: their application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists","volume":"22","author":"Cohen","year":"2022","journal-title":"Curr Diab Rep"},{"issue":"Suppl 1","key":"10.1016\/j.diabres.2022.110161_b0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13300-022-01277-1","article-title":"Prevention of cardiorenal complications with sodium-glucose cotransporter type 2 inhibitors: a narrative review","volume":"13","author":"Botana","year":"2022","journal-title":"Diabetes Ther"},{"issue":"1","key":"10.1016\/j.diabres.2022.110161_b0040","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12933-020-01197-z","article-title":"Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis","volume":"20","author":"Yamada","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"15","key":"10.1016\/j.diabres.2022.110161_b0045","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.diabres.2022.110161_b0050","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.diabres.2022.110161_b0055","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.diabres.2022.110161_b0060","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12933-022-01474-z","article-title":"The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs","volume":"21","author":"Giugliano","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.diabres.2022.110161_b0065","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects","volume":"18","author":"Barrera-Chimal","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"10.1016\/j.diabres.2022.110161_b0070","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.diabres.2022.110161_b0075","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1159\/000508670","article-title":"A prospective single-blind randomized trial of ramipril, eplerenone and their combination in type 2 diabetic nephropathy","volume":"10","author":"El Mokadem","year":"2020","journal-title":"Cardiorenal Med"},{"issue":"12","key":"10.1016\/j.diabres.2022.110161_b0080","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"24","key":"10.1016\/j.diabres.2022.110161_b0085","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.diabres.2022.110161_b0090","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in Type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.diabres.2022.110161_b0095","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.diabres.2022.110161_b0100","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ekir.2021.12.013","article-title":"The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, are present in patients With CKD treated with mineralocorticoid receptor antagonists","volume":"7","author":"Provenzano","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.diabres.2022.110161_b0105","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.diabres.2022.110161_b0110","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabres.2022.110161_b0115","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"7414","key":"10.1016\/j.diabres.2022.110161_b0120","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.diabres.2022.110161_b0125","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.diabres.2022.110161_b0130","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.diabres.2022.110161_b0135","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy","volume":"7","author":"Rossing","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1016\/j.diabres.2022.110161_b0140","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.diabres.2022.110161_b0145","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabres.2022.110161_b0150","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.diabres.2022.110161_b0155","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and Clinical Outcomes in Patients With Type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.diabres.2022.110161_b0160","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"23","key":"10.1016\/j.diabres.2022.110161_b0165","doi-asserted-by":"crossref","first-page":"e018889","DOI":"10.1161\/JAHA.120.018889","article-title":"Glucose metabolism in the kidney: neurohormonal activation and heart failure development","volume":"9","author":"Gronda","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.diabres.2022.110161_b0170","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.diabres.2022.110161_b0175","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-022-01512-w","article-title":"The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management","volume":"21","author":"Xu","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"10.1016\/j.diabres.2022.110161_b0180","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1097\/HJH.0000000000000719","article-title":"Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?","volume":"33","author":"Imprialos","year":"2015","journal-title":"J Hypertens"},{"key":"10.1016\/j.diabres.2022.110161_b0185","article-title":"Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review","volume":"8","author":"Fonseca-Correa","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1016\/j.diabres.2022.110161_b0190","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"issue":"48","key":"10.1016\/j.diabres.2022.110161_b0195","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1093\/eurheartj\/ehab497","article-title":"Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial","volume":"42","author":"Neuen","year":"2021","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.diabres.2022.110161_b0200","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jacc.2022.01.029","article-title":"Mineralocorticoid receptor antagonists and empagliflozin in patients with heart failure and preserved ejection fraction","volume":"79","author":"Ferreira","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.diabres.2022.110161_b0205","first-page":"1460","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: a Meta-Analysis of Individual Participant Data From Randomized","volume":"145","author":"Neuen","year":"2022","journal-title":"Controlled Trials Circulation"},{"issue":"4","key":"10.1016\/j.diabres.2022.110161_b0210","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.diabres.2022.110161_b0215","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.2215\/CJN.08580813","article-title":"Regulation of Potassium Homeostasis","volume":"10","author":"Palmer","year":"2015","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722009755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722009755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:23:07Z","timestamp":1759173787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822722009755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":43,"alternative-id":["S0168822722009755"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2022.110161","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2022.110161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110161"}}